Management

James Powers Chairman and CEO
James Powers
Chairman and CEO

Mr. Powers is Chairman and Chief Executive Officer of HemoShear Therapeutics. Prior to joining HemoShear in August 2008, Mr. Powers was a member of the executive team that took PRA International (now PRA Health Sciences) public in 2004. He transitioned PRA from a clinical data management company to a global clinical trials management organization, recruited its first operations leaders and led PRA’s business development activities. Mr. Powers served as an advisor to the UVA-Coulter Translational Research Partnership, which was funded by the Wallace H. Coulter Foundation and where he met HemoShear’s co-founders. Mr. Powers was on the Boards of CellzDirect and Averion during the time that both companies were successfully sold to larger R&D businesses. In 2014, Mr. Powers was selected to join PharmaVoice’s Top 100 most inspiring leaders in pharma. He currently serves on the board of Virginia BIO and is chairman of the Virginia BIO Foundation. Mr. Powers received a B.S. in administration and management science from Carnegie Mellon University.

Brian Wamhoff, PhD Head of Innovation
Brian Wamhoff, PhD
Co-founder and Head of Innovation

Dr. Wamhoff serves as HemoShear Therapeutics' Head of Innovation and is a company founder.  He is responsible for development and management of strategic team initiatives to ensure a robust pipeline of disease models to advance our drug discovery platform and early stage therapeutic programs.  Dr. Wamhoff has led teams to oversee the successful development of human vascular and liver disease models, as well as ongoing development of a tumor microenvironment system.  These advancements have been built in part by his role in securing significant NIH Small Business Innovation Research funding from five different NIH institutes. Additional activities include scientific publication strategy and activities, thought leader development and engagement activities, and intellectual property and patent strategy. Dr. Wamhoff, former Associate Professor at the University of Virginia, has co-founded multiple medical device and therapeutics companies.  He obtained a B.S. in biology with a minor in business administration from Rhodes College, where he was the 2011 Distinguished Alumnus; he received his Ph.D. in medical physiology from the University of Missouri.

John Reardon, PhD Head of R&D
John Reardon, PhD
Research & Development

John E. Reardon is the Head of Research and Development for HemoShear Therapeutics.  Prior to joining HemoShear in 2016, Dr. Reardon was the Chief Scientific Officer at Cardioxyl Pharmaceuticals, Inc where he successfully led development of a heart failure therapeutic in to Phase II, which was acquired by Bristol-Meyers Squibb in 2015 in a potential $2B deal.  Before joining Cardioxyl, Dr. Reardon was Executive Vice President and Chief Scientific Officer at Integrated Oncology Solutions, Inc. from 2007 – 2009. Dr. Reardon spent 19 years at GlaxoSmithKline PLC and its predecessor companies where he held a variety of leadership positions.  As Senior Vice President of Discovery Research Biology at GlaxoSmithKline he oversaw the biological science supporting lead discovery activities across all the therapeutic areas in the international GSK R&D organization.  Dr. Reardon received a B.A. from Willamette University, Oregon and a PhD degree in Chemistry from The Ohio State University, Ohio. He was an NIH post-doctoral fellow in the laboratory of Dr. Robert Abeles at Brandeis University before joining Burroughs-Wellcome Co. in 1986. 

 

Aric Holsinger, CPA CFO
Aric Holsinger, CPA
Chief Financial Officer

Aric Holsinger serves as HemoShear Therapeutics’ Chief Financial Officer and is responsible for the financial, tax, and accounting activities of the company. Prior to joining HemoShear, Mr. Holsinger was Chief Financial Officer of Cricket Media, an education technology company, for 7 years and led the company through a public offering and ultimately returned to private status. Previously Mr. Holsinger held CFO and VP Finance positions with MCT, a cellular telecommunications provider in Russia and Central Asia; the Baltimore Stallions, a franchise in the Canadian Football League; and the Baltimore Orioles.  Mr. Holsinger began his career with Arthur Andersen in Washington, DC and received his B.S. degree in accounting and management information systems from the University of Virginia.

Board of Directors

James Powers Chairman and CEO
James Powers
Chairman and CEO

Mr. Powers is Chairman and Chief Executive Officer of HemoShear Therapeutics. Prior to joining HemoShear in August 2008, Mr. Powers was a member of the executive team that took PRA International (now PRA Health Sciences) public in 2004. He transitioned PRA from a clinical data management company to a global clinical trials management organization, recruited its first operations leaders and led PRA’s business development activities. Mr. Powers served as an advisor to the UVA-Coulter Translational Research Partnership, which was funded by the Wallace H. Coulter Foundation and where he met HemoShear’s co-founders. Mr. Powers was on the Boards of CellzDirect and Averion during the time that both companies were successfully sold to larger R&D businesses. In 2014, Mr. Powers was selected to join PharmaVoice’s Top 100 most inspiring leaders in pharma. He currently serves on the board of Virginia BIO and is chairman of the Virginia BIO Foundation. Mr. Powers received a B.S. in administration and management science from Carnegie Mellon University.

John Brooks, III Board Member
John Brooks, III
Board Member

Mr. Brooks is the Managing Director of Healthcare Capital LLC, which specializes in advising innovative, early-stage life sciences companies. Mr. Brooks is on the board of a number of for-profit and not-for-profit organizations, including NeuroBo Pharmaceuticals, Cellnovo (chair), Thermalin Diabetes (chair), Noxilizer, Hygieia, College Diabetes Network (chair) and Suffolk University. Mr. Brooks is the former President and Chief Executive Officer of the Joslin Diabetes Center, a Boston based diabetes research, clinical care, and education organization. He has co-founded seven life sciences companies and was co-founder of Prism Venture Partners, a $1.25B venture capital firm. Prior to that, Mr. Brooks was a senior executive at Pfizer and Arthur Andersen. A native of Massachusetts, he holds an M.S. in Business Administration and a B.B.A. cum laude from the University of Massachusetts at Amherst.  He is a Certified Public Accountant.

Robert J. Gould, PhD Board Member
Robert J. Gould, PhD
Board Member

Dr. Gould is President and C.E.O. of Fulcrum Therapeutics, Inc., established in 2016. Fulcrum Therapeutics is a privately financed drug discovery and development company with a focus on genetically defined diseases. Prior to Fulcrum, Dr. Gould was President and C.E.O. of Epizyme, Inc., an oncology drug discovery and development company. In 2013, he led Epizyme through a successful public offering From November 2006 to March 2010, Dr. Gould served as Director of Novel Therapeutics at the Broad Institute of MIT and Harvard, a research institute. Prior to that, Dr. Gould was Vice President, Licensing and External Research, Merck Research Laboratories, at Merck & Co., Inc., where he held a variety of leadership positions during his 23-year tenure. Dr. Gould received a B.A. in chemistry from Spring Arbor College, a Ph.D. in biochemistry from the University of Iowa, and completed postdoctoral studies at Johns Hopkins University. Dr. Gould also serves on the boards of Fulcrum, Turnstone Biologics and Spring Arbor University.

W. M. Thompson, Jr. General Counsel
W. M. Thompson, Jr.
Board Member and General Counsel

W. McIlwaine (Mac) Thompson, Jr. is of counsel to the law firm of Woods Rogers PLC and specializes in representing companies in many diverse fields including biotechnology, information technology and oil and gas exploration. Mr. Thompson is secretary of Insmed Incorporated, a publicly traded biotechnology company, and is a member of the boards of Mestena Inc., an oil- and gas-exploration company, and Foundation Energy Management, LLC, which acquires oil- and gas-producing properties. He is a member of the investment advisory board of Tall Oaks Capital, a venture capital fund based in Charlottesville, and has represented many biotechnology companies in the Charlottesville area. He is also a member of the advisory board for the University of Virginia’s Heart and Vascular Center and general counsel to, and immediate past chair of, the board of the U.Va. Curry School of Education Foundation. Mr. Thompson graduated from Yale College in 1969 and the U.Va. Law School in 1972.

H. Thomas Watkins Board Member
H. Thomas Watkins
Board Member

Mr. Watkins was President, CEO and a Director of Human Genome Sciences (HGS) from 2004 until HGS was acquired by GlaxoSmithKline in 2012. During his tenure, HGS successfully developed and brought Benlysta to market in 2011, the first new lupus drug to be introduced in over 50 years. Prior to HGS, Mr. Watkins spent more than 20 years in senior roles at Abbott and its affiliates in the U.S. and Asia. During that time, he was President of TAP Pharmaceutical Products, Inc., which was jointly owned by Abbott and Takeda Pharmaceutical Company, where he led the growth of TAP from approximately $2 billion to over $4 billion in annual revenue. Previously, Mr. Watkins was a consultant with McKinsey and began his career with Arthur Andersen. He is former Chairman of the Biotechnology Industry Organization (BIO) and continues to serve on its Board. He is currently Chairman of the Board of Directors of Vanda Pharmaceuticals, Inc., and on the Board of Horizon Pharma plc. He also serves on the Board of Visitors of the College of William & Mary and the Board of the Ann and Robert H. Lurie Children’s Hospital of Chicago. Mr. Watkins received his B.B.A. in accounting from William & Mary and his M.B.A. from the University of Chicago Graduate School of Business, now the Booth School of Business.

Reginald Woods Board Member
Reginald Woods
Board Member

Mr. Woods is a founding investor and founding Board member of HemoShear Therapeutics. He was CEO of Butler International, where he led a successful corporate turnaround, public offering, listing on the NYSE, and eventual cash sale of the company managed by a major investment bank.  He later co-founded a merger and acquisition consulting practice specializing in the insurance industry. His Board affiliations include Scitent, Inc. and the University of Virginia Heart and Vascular Center.  He was co-founder of the Keswick Community Foundation and has served on the Board and Executive Committee of Habitat for Humanity of Greater Charlottesville.  He earned B.S. and M.S. degrees in engineering and an M.B.A. from Cornell University.

Advisors

PROPIONIC ACIDEMIA AND METHYLMALONIC ACIDEMIA CLINICAL ADVISORY BOARD

Marshall Summar, M.D., Children's National Medical Center, Chief Genetics and Metabolism; Margaret O’Malley Professor of Genetic Medicine; National Organization of Rare Diseases (NORD, Chairman of the Board)

Moeen Alsayed, M.D., King Faisal Specialist Hospital (KSA), Chairman of Medical Genetics

Mattias Baumgartner, M.D., University of Zurich, Head of the Division of Metabolic Diseases at the Children's Hospital Zurich

Greg Enns, M.D., Stanford University, Professor of Pediatrics (Genetics) at the Lucile Salter Packard Children's Hospital

Nicola Longo, M.D., Ph.D., University of Utah, Chief of the Division of Medical Genetics; Professor of Pediatrics at Primary Children’s Medical Center

 

NASH ADVISOR

Arun Sanyal, M.D.,  NAFLD/NASH Consultant: Professor and Chair, Division of Gastroenterology, Hepatology and Nutrition, VCU; Chairman, NIH NASH Research Network.

 

R&D ADVISORS

Tony Bower, Ph.D., Reimbursement Consultant: President, BRG LLC; VP Global Pricing, Reimbursement and Health Economics, Synageva BioPharma; Head of Pricing, Amgen; Senior Economist, RAND.

John Dillberger, DVM, Ph.D. Diplomate ACVP and ABT, Fellow IATP. Toxicology Consultant: J Dillberger LLC; Charles River Labs; Triangle Pharmaceuticals; Glaxo Wellcome

Mark Hayes, Ph.D., Regulatory Affairs Consultant: HayesWays LLC; SVP Regulatory Affairs, Synageva BioPharma; Genzyme; FDA

Donald Hertzog, Ph.D., Chemistry Consultant: Don Hertzog Consulting LLC; VP Lead Identification, Abide Therapeutics; RTP Site Head, Department of Medicinal Chemistry, Molecular Discovery Research, GSK

Mehmood Khan, M.D., Medical Advisor: Vice Chairman of PepsiCo, Inc.; Royal College of Physicians, London; American College of Endocrinology;

John LaMattina, Ph.D., Business Strategy Consultant: President, Pfizer R&D; Board Director, PureTech Ventures